Showing 1407 results
-
Press release /New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Story /Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
-
Press release /Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
-
Press release /Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
-
Press release /Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal…
-
Story /Novartis researchers are using new technologies, such as DNA-encoded libraries, to find new ways to treat disease.
-
Story /With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.
-
Story /Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
Story / -
Press release /If approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologic Positive CHMP opinion based on evidence from extensive analytical…